Enhancing Care for Severe Asthma Patients Webinar

July 16, 2026

Severe asthma remains a significant clinical challenge, with patients experiencing frequent exacerbations and suboptimal outcomes despite available evidence-based treatments. Current gaps in care include delays in diagnosis, underutilization of biologic therapies, and insufficient management of comorbidities and social determinants impacting patient health. Addressing these gaps is critical to improving patient outcomes and reducing healthcare disparities.

This 60-minute webinar will review severe asthma diagnosis and treatment, evaluate education materials and decision aids to support shared decision-making, and study comorbidities that impact severe asthmatics and their outcomes.

This webinar is supported by an independent medical education grant from GSK.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allergy advanced practice providers, and allergy fellows.

Learning Objectives

After participating in this webinar, participants should be better able to:

  1. Develop clinical pathways on severe asthma diagnosis and treatment.
  2. Create a plan to use education materials and decision aids to support shared decision making.
  3. Understand the comorbidities that impact severe asthmatics and their outcomes.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
07/16/2026
Course expires: 
12/31/2026
Event starts: 
07/16/2026 - 7:00pm CDT
Event ends: 
07/16/2026 - 8:00pm CDT
Add to calendar: 

William C. Anderson, III, MD, FACAAI
Dr. William Anderson is an Associate Professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine. Dr. Anderson is Clinical Medical Director for the Allergy and Immunology Section, Co-Director of the Improving Pediatric to Adult Care Transitions (ImPACT) Program and Director of the Multidisciplinary Asthma Clinic. Dr. Anderson's clinical and scholarly interests include pediatric-to-adult transitions of care; difficult-to-treat and severe asthma; and the incorporation of technology in medicine.
Disclosures: no relevant financial relationships to disclose.

Alan P. Baptist, MD, FACAAI
Dr. Alan Baptist is a Professor in the Department of Internal Medicine and is the Division Head of Allergy and Clinical Immunology at Henry Ford Health. Dr. Baptist obtained his medical degree from Loyola University of Chicago and a Master of Public Health degree from Wayne State University. He completed his internship, residency, and fellowship at the University of Michigan in Ann Arbor. He was a member of the NIH 2020 Asthma Guidelines Update Committee. He is the founder and director of the Henry Ford Health Comprehensive Asthma Program. He has published over 100 articles, primarily dealing with asthma.
Disclosures: GSK: consultant and researcher

Moderator:
Angela Duff Hogan, MD, FACAAI
Dr. Angela Duff Hogan is Professor of Pediatrics at Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School in Norfolk, VA in the Allergy & Immunology Division at the Children’s Hospital of the King’s Daughters and is a senior partner of Children’s Specialty Group. Dr. Hogan is a fellow of ACAAI, AAAAI, and AAP. She is chair of the ACAAI Asthma Committee, and member of the executive committee of SOAI for the AAP.
Disclosures: no relevant financial relationships to disclose.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.

Register here: Enhancing Care for Severe Asthma Patients Webinar